Krystal Biotech, Inc. 8-K

What Happened

• Krystal Biotech, Inc. (KRYS) filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held May 19, 2026 (filed May 20, 2026). Stockholders elected two Class III directors, ratified KPMG LLP as the independent registered public accounting firm for fiscal 2026, approved a non-binding vote on executive compensation, and approved a Non-Employee Director Compensation Policy (vote by unaffiliated stockholders). The report was signed by Chairman and CEO Krish S. Krishnan.

Key Details

• Director elections (Class III, three-year terms):
  • Krish S. Krishnan: For 23,802,920; Withheld 3,079,194; Broker non-votes 1,581,473.
  • Christopher Mason: For 22,581,854; Withheld 4,300,260; Broker non-votes 1,581,473.
• Auditor ratification:
  • KPMG LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2026 — For 28,443,155; Against 15,434; Abstentions 4,998.
• Advisory (non-binding) say-on-pay:
  • Approved for named executive officer compensation for FY 2025 — For 25,679,318; Against 1,195,788; Abstentions 7,008; Broker non-votes 1,581,473.
• Non-Employee Director Compensation Policy:
  • Approved by unaffiliated stockholders — For 21,374,021; Against 2,349,550; Abstentions 3,158,543; Broker non-votes 1,581,473. (Certain board members and litigation defendants refrained from voting.)

Why It Matters

• The vote confirms Krystal’s current board composition and governance direction, with Krishnan and Mason retained as Class III directors.
• Ratification of KPMG ensures auditor continuity for fiscal 2026, a routine but important governance item for financial oversight.
• The advisory approval of executive pay indicates majority shareholder support for the company’s 2025 compensation disclosures (non-binding).
• Approval of the Non-Employee Director Compensation Policy (by unaffiliated holders) formalizes director pay practices, which can affect governance perceptions and alignment with investor expectations.